Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy).

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Fertility and Sterility

• Publication date

  2000-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0015-0282(99)00636-6PMID 10731543
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover

  2004cited by this paper
• Effect of Treatment with GnRH Agonists on New Markers of Bone Metabolism

  1999cited by this paper
• Leuprolide Acetate Depot and Hormonal Add‐Back in Endometriosis: A 12‐Month Study

  1998cited by this paper
• The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover.

  1998cited by this paper
• Reduction of bone mineral density by gonadotropin‐releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration

  1996cited by this paper
• Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis.

  1996cited by this paper
• Urinary N‐Telopeptides to Monitor Bone Resorption While on GnRH Agonist Therapy

  1996cited by this paper
• Excretion of urinary N-telopeptides reflects changes in bone turnover during ovarian suppression and indicates individually variable estradiol threshold for bone loss.

  1996cited by this paper
• Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain.

  1995cited by this paper
• Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis.

  1995cited by this paper
• Low dose intranasal nafarelin for the treatment of endometriosis

  1994cited by this paper
• Nafarelin in the treatment of endometriosis. Dose management.

  1994cited by this paper
• Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.

  1994cited by this paper
• Treatment of Uterine Myomas with GnRH Agonists

  1993cited by this paper
• The Use of GnRH Agonists in the Medical Therapy of Endometriosis in the Woman with Pain

  1993cited by this paper
• Hormone treatment of endometriosis: the estrogen threshold hypothesis.

  1992cited by this paper
• Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial.

  1992cited by this paper
• Spontaneous and steroid-induced recurrence of endometriosis after suppression by a gonadotropin-releasing hormone antagonist in the rat.

  1991cited by this paper
• Treatment of Endometriosis With a Long-Acting Gonadotropin-Releasing Hormone Agonist Plus Medroxyprogesterone Acetate

  1990cited by this paper
• Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?

  1990cited by this paper
• Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial.

  1988cited by this paper
• The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism.

  1988cited by this paper
• Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin).

  1986cited by this paper
• Human uterine endometrium and endometriotic tissue transplanted into nude mice. Morphologic effects of various steroid hormones.

  1985cited by this paper
• Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness.

  1981cited by this paper
• Dosage aspects of danazol therapy in endometriosis.

  1977cited by this paper

• Extended GnRH Agonist and NETA Add-Back: An Effective and Safe Option for Refractory Endometriosis/Adenomyosis Pain

  2025cites this paper
• Chrysin-loaded PLGA nanoparticles alleviate the implantation of endometriotic lesions via attenuation of peritoneal inflammation and downregulating NF-κB activation-driven expression of angiogenic factors

  2025cites this paper
• A study on the efficacy and safety of long‐term adjusted low‐dose gonadotropin‐releasing hormone agonist therapy for uterine fibroids and adenomyosis

  2024cites this paper
• Gonadotropin-Releasing Hormone (GnRH)/GnRH Receptors and Their Role in the Treatment of Endometriosis

  2023cites this paper
• Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not?

  2023cites this paper
• Agonists of gonadotropin-releasing-hormone and add-back-therapy

  2023cites this paper
• Gonadotropin-releasing hormone analogues for endometriosis.

  2023cites this paper
• Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis

  2020cites this paper
• Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment

  2017cites this paper
• Low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for successful long-term management of adenomyosis associated with cerebral venous and sinus thrombosis from low-dose oral contraceptive use.

  2017cites this paper
• Curative effect of 1.88‐mg and 3.75‐mg gonadotrophin‐releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study

  2017cites this paper
• Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy.

  2017influential citation
• The Characterisation of FcγRIIa Antagonists

  2016cites this paper
• Endometriosis

  2015cites this paper
• Integrated Pharmacometrics and Systems Pharmacology Model-Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis

  2012cites this paper
• Hormonal strategy for the primary or secondary treatment of endometriosis

  2012cites this paper
• Clinical Aspects of Endometriosis

  2010cites this paper
• Gonadotrophin-releasing hormone analogues for pain associated with endometriosis.

  2010cites this paper
• [Endometriosis: necessary and sequential therapeutic procedures and guidelines].

  2010cites this paper
• Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.

  2009cites this paper
• Successful long-term management of adenomyosis associated with deep thrombosis by low-dose gonadotropin-releasing hormone agonist therapy.

  2009cites this paper
• Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis.

  2009cites this paper
• GnRH-Analoga und Add-back-Verfahren

  2008cites this paper
• Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide GnRH Antagonist Elagolix

  2008cites this paper
• Noninvasive assessment of ectopic uterine tissue development in rats using magnetic resonance imaging.

  2007cites this paper
• Gynaecology Forum, vol. 11, no. 2, 2006

  2006cites this paper
• Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902).

  2006cites this paper
• Receptor (NBI-42902) Administered Nonpeptide Antagonist of the Gonadotropin-Releasing Hormone Suppression of Serum Luteinizing Hormone in Postmenopausal Women by an Orally

  2006cites this paper
• Emerging drugs in endometriosis

  2006cites this paper
• New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists

  2005cites this paper
• GnRH-antagonists in reproductive medicine

  2005cites this paper
• Medical management of endometriosis: a systematic review.

  2004cites this paper
• Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density.

  2003cites this paper
• Gonadotropin Releasing Honnone Agonist and Antagonist for Endometriosis

  2003cites this paper
• Neue Trends in der konservativen und operativen Therapie der Endometriose

  2002cites this paper
• The role of LHRH agonists and antagonists.

  2001cites this paper